<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">At present, there are no specific treatment with confirmed efficacy for COVID-19 and the therapeutic protocol is as per best supportive care for any respiratory disease. However, both antivirals and immune modulators warrant further investigation especially considering the biphasic pattern of immune responses during the diseases course
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup>. Several drugs with potential antiviral activities are under active investigation. More recently, the WHO also launched multinational trial to validate four drugs especially in combinations, including ritonavir/lopinavir, lopinavir and ritonavir with interferon-beta, chloroquine and/or remdesivir. Several clinical trials, over 1673, have been registered worldwide and are listed at 
 <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">www.clinicaltrials.gov</ext-link> (specifically see: 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=covid-19" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/results?cond=covid-19</ext-link>). A selected clinical trials with possible significance are listed in Table 
 <xref rid="Tab2" ref-type="table">2</xref>.
</p>
